This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,828,350
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
CIHR · 2023 · Principal investigator
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
Principal investigators: Kolinsky, Michael; Jafri, mariam
Keywords: Dna Damage Response (Ddr) Genes; Economics; Genomic Testing; Metastatic Castration-Resistant Prostate Cancer; Patient-Reported Outcomes; Personalized Medicine; Platinum Chemotherapy; Quality Of Life; Randomized Controlled Trial
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.